en

PRODUCT DETAIL

Bortezomib Fresenius Kabi 3,5 mg prášok na injekčný roztok

Code 2970D
MA number EU/1/19/1397/001
Product Form: plv ino 1x3,5 mg (liek.inj.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XG Proteasome inhibitors
L01XG01 Bortezomib
Shelf life: 24
Container: glass vial
Route of admin.: Subcutaneous and intravenous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(1) generic application
MA issued: 14.11.2019
Validity: 14.11.2024
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 09.08.2021
eu-flag.png sk-flag.png